What Are Parenteral Controlled Substances?

Parenteral controlled substances are government-regulated drugs that are delivered by injection or infusion rather than swallowed, inhaled, or applied to the skin. The word “parenteral” comes from Greek roots meaning “outside the intestine,” and it covers any route that bypasses the digestive tract: intravenous (IV) drips, intramuscular shots, subcutaneous injections, epidural catheters, and more.¹ The “controlled” part means these drugs carry abuse or dependence potential serious enough for the government to restrict how they are prescribed, stored, and disposed of. Put the two halves together and you get a category of medications that hospitals rely on daily but handle with extraordinary caution.

What Makes a Drug Both Parenteral and Controlled

A substance lands on the controlled list when it has recognized medical value but also a meaningful risk of misuse or physical dependence. In the United States, the Controlled Substances Act sorts these drugs into five schedules, from Schedule I (no accepted medical use, high abuse potential) through Schedule V (low abuse potential). Most parenteral controlled substances used in hospitals fall into Schedule II, III, or IV. Think of injectable morphine, fentanyl, and hydromorphone in Schedule II; ketamine in Schedule III; and midazolam or diazepam in Schedule IV.²

What sets the parenteral form apart from pills or patches is speed and reliability. An IV push of morphine reaches the brain in seconds, while an oral tablet has to dissolve, pass through the stomach lining, and survive first-pass metabolism in the liver before any of it reaches systemic circulation. That speed is the whole point in settings like surgery, trauma, or status epilepticus, where minutes matter. But it also magnifies the risk: a dosing error or an adverse reaction can escalate far faster when the drug is already in the bloodstream.

Common Clinical Uses

Parenteral controlled substances show up across nearly every acute-care setting. The broadest use is postoperative pain management. Opioids injected or infused through an IV line have long been the default for controlling pain after surgery, though the field has been shifting toward multimodal approaches that combine opioids with non-opioid agents to reduce side effects like nausea and slowed gut motility.³ Among the IV opioids used for this purpose, systematic reviews of randomized trials have found that intravenous oxycodone tends to require lower total doses than fentanyl or sufentanil for comparable pain relief, while performing similarly to morphine.⁴

Emergency medicine is another major arena. When someone arrives seizing, the priority is stopping the seizure fast. A large trial found that intramuscular midazolam stopped seizures before hospital arrival in about 73% of patients, compared with about 63% for intravenous lorazepam, partly because the IM injection could be given immediately without waiting for IV access.⁵ In children, where getting a needle into a tiny, convulsing vein is even harder, research supports non-IV midazolam, including buccal (inside the cheek) administration, as an effective first-line option over rectal diazepam.⁶

Ketamine occupies a slightly different niche. Classified as a dissociative agent, injectable ketamine is used for procedural sedation, acute pain in emergency departments, and increasingly for refractory neuropathic pain. Case reports have documented successful IV ketamine infusions at sub-anesthetic doses for chronic pain combined with severe depression, even in pediatric patients.⁷ Its rapid onset and relatively short duration make it useful in situations where conventional opioids are either insufficient or contraindicated.

Intensive Care and the Weaning Challenge

Critically ill patients on mechanical ventilators often receive continuous IV opioid infusions for days or weeks. The longer those infusions run and the higher the cumulative dose, the harder it becomes to taper them off. A retrospective analysis of 240 ventilated adults found that roughly three-quarters experienced at least one failed opioid weaning attempt, with higher total exposure and larger percentage drops in dose both predicting failure.⁸ This is a genuine clinical bottleneck: patients who cannot be weaned off opioids stay on the ventilator longer, face higher infection risk, and occupy ICU beds that are perpetually in short supply.

One emerging strategy involves transitioning patients from continuous IV opioid drips to low-dose buprenorphine, a partial opioid agonist. A pilot study in neurocritical care patients showed that those started on buprenorphine had roughly 12 fewer ventilator days on average compared with a matched group that was not, and none of the buprenorphine patients developed withdrawal symptoms, versus a third of the comparison group.⁹ The results are preliminary, but the concept of using a controlled substance to get off a different controlled substance illustrates how nuanced parenteral opioid management has become.

Palliative Care and Subcutaneous Delivery

At the other end of the care spectrum, parenteral controlled substances play a central role in comfort care for dying patients. When someone can no longer swallow pills or absorb oral medication reliably, continuous subcutaneous infusion (CSCI) provides a steady stream of opioid through a small needle placed under the skin. A study of palliative care patients found that the proportion reporting severe or overwhelming pain dropped from about 45% to 19% after CSCI was started, with only a modest increase in total opioid dose. Alertness fell by a single point on a ten-point scale, and no serious side effects required stopping the infusion.¹⁰ For patients and families concerned that stronger pain control means heavy sedation, those numbers are reassuring.

Routes Beyond the Standard IV Line

Intravenous delivery gets the most attention, but parenteral controlled substances can reach much more targeted destinations. Epidural catheters thread into the space surrounding the spinal cord and deliver opioids (often combined with local anesthetics) directly to the nerve roots handling pain signals. Patient-controlled epidural analgesia, or PCEA, lets you press a button to receive a bolus dose, with a programmable lockout interval to prevent overdosing. Research has found that longer lockout intervals actually reduce total drug consumption without worsening pain control.¹¹

Intrathecal delivery goes a step further, placing medication directly into the cerebrospinal fluid. This route requires far smaller doses because the drug bypasses most of the barriers between it and the spinal cord. Permanent implantable pumps with programmable dosing schedules now allow intrathecal opioid delivery for patients with chronic pain who have not responded to less invasive treatments.¹² The technology has evolved substantially, moving from basic external catheters to fully internalized programmable systems that can be adjusted wirelessly by a clinician.

Safety Risks Specific to Injectable Controlled Substances

The rapid onset that makes parenteral opioids effective also makes them dangerous. The most feared complication is respiratory depression, where breathing slows or stops. A case-control study of hospitalized adults identified several independent risk factors for severe opioid-induced respiratory depression: kidney failure roughly doubled the odds, the first 24 hours after starting an opioid carried nearly twice the risk compared with later days, and concurrent use of other sedating medications like benzodiazepines added further risk. Older age was also a factor, with odds climbing modestly for each additional year.¹³ That first-24-hour window is worth noting: it means the period right after surgery, when patients are often receiving their initial opioid doses, is precisely when monitoring needs to be most vigilant.

Parenteral opioids can also interfere with other drugs you are taking by mouth. When IV morphine and oral acetaminophen are given together, the morphine slows gut motility enough to reduce how much acetaminophen the body absorbs. Peak blood levels of acetaminophen dropped by roughly a third during morphine co-administration, then spiked sharply once the morphine was stopped, creating unpredictable swings in a drug most people assume is simple and safe.¹⁴

There are also risks at the injection site itself. Extravasation, where fluid leaks out of the vein into surrounding tissue, is a recognized hazard of any IV infusion. With controlled substances, the consequences can range from local irritation to tissue death. Case reports have documented compartment syndrome requiring emergency surgery in patients receiving parenteral nutrition through peripheral lines with pressurized pumps.¹⁵ While this specific complication involves nutrition formulas rather than opioids, the underlying problem of catheter-related tissue injury applies broadly to any continuous parenteral infusion.¹⁶

Diversion Prevention Inside Hospitals

Because injectable controlled substances are potent, fast-acting, and physically compact, they are prime targets for theft or tampering by healthcare workers with substance use disorders. Hospitals are required to maintain detailed records of every vial dispensed, administered, and discarded. Disposal of unused portions typically must be witnessed by a second staff member, and many facilities use automated dispensing cabinets that track who accessed which drug and when.¹⁷

In practice, the system has gaps. A national survey of U.S. hospital pharmacies found that while waste and disposal procedures were generally well-followed, training on how to detect signs of medication tampering was far less common.¹⁸ Tampering can be subtle: a nurse might withdraw a full vial, inject only part of it into the patient, pocket the rest, and document the full dose as given. Without frequent auditing of dispensing records against patient outcomes, these patterns can go undetected for months. The consequences extend beyond the diverted drug itself, since patients end up undertreated for pain while a caregiver’s impairment puts everyone in the unit at risk.

Sterile Compounding Standards

Any drug that enters the bloodstream must be sterile, but parenteral controlled substances often need additional preparation: diluting a concentrated vial, combining drugs in a single syringe, or mixing custom infusion bags for patient-controlled analgesia pumps. In the United States, USP Chapter 797 sets the standard for sterile compounding practices and is considered the benchmark for safety.¹⁹ The standard covers everything from the physical environment (air quality, surface cleaning) to personnel training and beyond-use dating. Violations made national headlines in 2012 when contaminated compounded medications caused a fungal meningitis outbreak, a reminder that the sterility chain for injectable drugs is only as strong as its weakest link.

What Happens When Supply Runs Short

Parenteral controlled substances are among the drugs most frequently affected by manufacturing shortages. The reasons are varied: limited numbers of sterile injectable manufacturers, regulatory shutdowns of production facilities, and raw-ingredient supply problems. When a major parenteral opioid shortage hit, one hospital system reported that total inpatient opioid dispensing fell from about 2.0 million morphine milligram equivalents to 1.4 million, and patient-controlled analgesia pump use dropped by roughly two-thirds. The gap was filled partly by increased use of IV acetaminophen and regional anesthesia techniques.²⁰ Interestingly, patients did not appear to suffer dramatically worse pain outcomes, which raises an uncomfortable question about whether baseline parenteral opioid use had been higher than strictly necessary.

Injection Drug Use and Harm Reduction

The same pharmacological properties that make parenteral controlled substances valuable in hospitals make them dangerous on the street. Illicit injection of opioids and other controlled substances carries risks that go well beyond overdose. A national survey of people entering treatment for opioid use disorder found that over 63% of those who had injected drugs reported at least one injection-related infection. Nearly a third had drained abscesses on their own without medical help, and about a fifth had obtained antibiotics from non-healthcare sources.²¹ Non-sterile practices were common, including sharing needles with visibly ill individuals and reusing needles that had been used to drain wounds.

Harm reduction programs attempt to address these risks without requiring abstinence as a precondition. Syringe service programs distribute clean injection equipment to reduce transmission of HIV and hepatitis C. Supervised injection facilities, operating legally in several countries and in a small number of U.S. jurisdictions, provide a medically monitored environment where people can inject pre-obtained drugs with naloxone and emergency care immediately available if an overdose occurs. Emergency medicine organizations have increasingly recognized these programs as complementary to treatment-focused approaches like buprenorphine induction, particularly for patients who are not ready to stop using.²² The connection back to clinical parenteral controlled substances is not incidental: the same morphine molecule that flows through a hospital IV line may circulate illicitly in powder form, and understanding the pharmacology in one context informs safety efforts in the other.

How Parenteral Opioid Use Has Evolved Over Time

Opioids in surgical settings predate modern anesthesia by centuries. Derivatives of opium were used as pain relievers long before ether and chloroform arrived. Once inhalational anesthetics became widespread, injectable opioids shifted into supporting roles: premedication before surgery, supplements during the procedure, and pain control afterward. The ongoing push to develop new synthetic opioids has always been driven by the desire to fine-tune how fast the drug hits, how long it lasts, and how cleanly it wears off.²³ Fentanyl, for example, was designed specifically for its rapid onset and short duration, making it ideal for procedures where pain is intense but brief. Remifentanil pushed this logic even further, breaking down so quickly in the blood that its effects essentially vanish within minutes of stopping the infusion. Each new agent was an attempt to make parenteral opioid use more precise and, in theory, safer. The opioid crisis has complicated that narrative, but the pharmacological goals remain the same: deliver the strongest pain relief at the exact moment it is needed, with the fewest lingering effects once it is not.